兆科眼科(06622.HK)TONO-i取得供測量眼壓醫療器械註冊證
兆科眼科(06622.HK)公布,公司已向國家藥品監督管理局取得TONO-i的醫療器械註冊證。TONO-i為一款創新的眼壓計,有別於傳統的接觸式眼壓計,TONO-i可於無需麻醉下使用。
於2022年11月,公司與C&VTech達成一項有關TONO-i的獨家分銷協議。根據該協議的條款,公司擁有於大中華登記、進口、推廣、分銷、營銷及出售TONO-i的獨家權利。該等權利其後透過合約修訂擴大至包括泰國及馬來西亞,自2024年8月起生效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.